Raleigh, NC (PRWEB) April 04, 2012
Agile Sciences has been awarded $1,030,000 from the National Institutes of Health (NIH) to advance pre-clinical development of the company’s novel anti-biofilm treatment for dental caries. The Phase II SBIR Award follows a $252,000 Phase I SBIR Award that was granted to Agile Sciences in August 2010.
Dental caries are caused by pathogenic bacteria in the mouth that exist in the form of a protected biofilm, commonly referred to as plaque. Biofilms are very difficult to remove from tooth and oral tissue surfaces. Agile Sciences has developed proprietary compounds that are able to both inhibit the formation of oral biofilms as well as disperse existing biofilms.
Principal Investigator Dr. Angela Pollard stated, “We are grateful to the NIH for the opportunity to build on the exciting results generated in Phase I of this project. In Phase II, we will conduct a more comprehensive evaluation of the efficacy and safety of our novel biofilm-dispersing compounds.”
Dr. Eva Garland, Agile Sciences’ VP of Research and Development, commented, “We are particularly pleased to receive this Phase II Award just 18 months after receipt of our Phase I award for this project. The Phase II award will provide important continuity in the development of our anti-biofilm molecules for improving oral health.”
Agile Sciences’ co-founder, Dr. John Cavanagh, stated, “Given that 85% of the population suffers from dental caries, a treatment that more effectively reduces the incidence of this disease has the potential to be of significant commercial value.”
Agile Sciences’ Phase II project will commence immediately and continue for two years.
About Agile Sciences:
Agile Sciences is headquartered on North Carolina State University's Centennial Campus. The company was founded in 2007 to provide commercial solutions to those industries plagued by the effects of biofilms. The company's proprietary Agilyte® compounds have been shown to be effective in dispersing biofilms and overcoming bacterial resistance mechanisms. For additional information, please visit: http://www.agilesci.com.